Fig. 3

Distribution of lymphocyte subpopulations in the patients’ PitNets: comparison between two patients. a1 – distribution of T-cells; a2 – distribution of B-cells; a3 – distribution of NK-cells; a4 – distribution of NK-cell subpopulations; b1 – distribution of CD4 + & CD8 + subpopulations gated from CD3 + T-cells;; b2 – distribution of CD45RA + naïve and CD45RA- memory CD4 + T-cells; b3—distribution of CD45RA + naïve and CD45RA- memory CD8 + T-cells; b4—distribution CD4 + T-cells with PD-1 expression; b5—distribution CD8 + T-cells with PD-1 expression; c1—distribution of Tregs; d1 – distribution of perforin + lymphocytes; d2 – distribution of Granzyme B + lymphocytes; d3—distribution of perforin + granzyme B + NK-cells; d4—distribution of perforin + granzyme B + CD8 + T-cells; e1 – perforin-mediated cytotoxicity index of CD8 + T-cells; e2 – granzyme B-mediated cytotoxicity index of CD8 + T-cells; e3 – perforin-mediated cytotoxicity index of CD16 + NK-cells; e4 – granzyme B-mediated cytotoxicity index of CD16 + NK-cells; e5 – perforin-mediated cytotoxicity index of CD56 + NK-cells; e6 – granzyme B-mediated cytotoxicity index of CD56 + NK-cells; f1 – frequency of macrophages among all cell types in PitNETs; f2 – distribution of macrophage M1 and M2 subpopulations; Data for both patients are represented as values of their relative frequencies. HD refers to healthy donors, P. – patient P., R.1 – Patient R. in October 2023 at the first relapse; R.2 – Patient R. in April 2024 at the second relapse; * refers to the difference between patients; ** refers to the difference between two relapses of Patient R